This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Illumina (ILMN) Beats on Q2 Earnings, Lowers 2024 Sales View
by Zacks Equity Research
Illumina's (ILMN) Q2 earnings and revenues surpass estimates in a challenging global macroeconomic environment.
Haemonetics (HAE) Q1 Earnings Miss Estimates, Gross Margin Rises
by Zacks Equity Research
Haemonetics' (HAE) earnings lag estimates in the first quarter of fiscal 2025. However, the company remains confident about its strategy for sustained profitable growth.
Prestige Consumer's (PBH) Q1 Earnings Beat, Margins Shrink
by Zacks Equity Research
Prestige Consumer (PBH) first-quarter sales bear the brunt of the ongoing supply chain challenges in the Clear Eyes business.
Insulet (PODD) Q2 Earnings Miss Estimates, '24 Sales View Raised
by Zacks Equity Research
Insulet's (PODD) second-quarter performance benefits from the continued high demand for Omnipod 5.
Envista (NVST) Q2 Earnings & Revenues Miss, Margins Fall
by Zacks Equity Research
Envista's (NVST) Spark division sales witness a slowdown in the second quarter due to the deferment of a larger portion of case revenues.
Veracyte (VCYT) Q2 Earnings Beat Estimates, '24 Sales View Up
by Zacks Equity Research
Veracyte's (VCYT) second-quarter 2024 performance reflects the strength of its testing business.
National Vision (EYE) Tops Q2 Earnings, Lowers '24 Outlook
by Zacks Equity Research
National Vision (EYE) delivers an earnings beat in the second quarter of 2024 and announces new transformative actions for long-term growth.
Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised
by Zacks Equity Research
Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term revenue growth rate target.
Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down
by Zacks Equity Research
Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.
Zimmer Biomet (ZBH) Beats on Q2 Earnings, Cuts Revenue View
by Zacks Equity Research
Zimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.
STERIS (STE) Q1 Earnings Beat Estimates, Operating Margin Falls
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of the operating margin is concerning.
Globus Medical (GMED) Q2 Earnings Top Estimates, '24 View Up
by Zacks Equity Research
Globus Medical (GMED) delivers massive sales and earnings growth in the second quarter of 2024. However, margins contract.
CVS Health (CVS) Beats Q2 Earnings, Narrows '24 EPS Outlook
by Zacks Equity Research
CVS Health (CVS) delivers a year-over-year improvement in revenues, driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments.
Bruker (BRKR) Q2 Earnings Meet Mark, '24 Revenue Outlook Raised
by Zacks Equity Research
Bruker (BRKR) delivers robust revenue growth in the second quarter despite soft general market conditions.
IDEXX (IDXX) Q2 Earnings Miss Estimates, 2024 View Down
by Zacks Equity Research
IDEXX's (IDXX) Q2 earnings miss estimates but revenues meet the same.
Henry Schein (HSIC) Q2 Earnings Surpass, 2024 Guidance Slashed
by Zacks Equity Research
Henry Schein's (HSIC) second-quarter results reflect an improvement in sales trends in distribution businesses.
Intuitive Surgical (ISRG) Rises 5% Post Earnings: What's Next?
by Indrajit Bandyopadhyay
Intuitive Surgical (ISRG) is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.
Intuitive Surgical and American Airlines Industries have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Intuitive Surgical and American Airlines Industries have been highlighted as Zacks Bull and Bear of the Day
Tandem Diabetes (TNDM) Q2 Earnings Beat, '24 View Raised
by Zacks Equity Research
Tandem Diabetes' (TNDM) top and bottom lines outpace estimates in the second quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Bull of the Day: Inuitive Surgical (ISRG)
by Andrew Rocco
Intuitive Surgical is a leading innovator in robotic-assisted surgery with its da Vinci Surgical System. The company benefits from an aging population and a solid competitive moat.
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered
by Zacks Equity Research
Bio-Rad (BIO) witnesses growth in the second quarter across the Clinical Diagnostics segment, primarily driven by an increased demand for quality control and blood typing products.
Omnicell (OMCL) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Omnicell's (OMCL) Q2 results outpace expectations despite a challenging customer environment.
Is Trending Stock Intuitive Surgical, Inc. (ISRG) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.